Sector expected to reach $21.7 billion by 2031 at a CAGR of 9.6%


Dublin, May 12, 2023 /PRNewswire/ — “Global Acute Bacterial Skin and Skin Structure Infection Treatment Market Report and Forecast 2023-2031” report added of ResearchAndMarkets.com Recruitment.

research and market logo

research and market logo

The global acute bacterial skin and skin structure infections (ABSSSI) treatment market size is $9.5 billion It is projected to grow at a CAGR of 9.6% in 2022 and reach a value of 9.6% during the forecast period of 2023-2031. $21.7 billion By 2031.

The market growth can be attributed to the increasing prevalence of ABSSSI, growing awareness of skin health, and advances in treatment options.

Acute Bacterial Skin and Structural Skin Infections (ABSSSI) Treatment Market: An Introduction

ABSSSI treatment refers to medical care provided to people with acute bacterial skin and skin structure infections. Treatment options include antibiotics, surgical interventions, and other ancillary services such as wound care and infection prevention. The increasing prevalence of his ABSSSI, including cellulitis, abscesses, and wound infections, has increased the demand for ABSSSI treatment. Other factors such as growing awareness of skin health, increasing government initiatives, and rising demand for innovative treatment options are also expected to drive the market growth.

Advancements in medical technology have played a key role in the growth of the ABSSSI treatment market. New antibiotics, targeted therapies, and improved surgical techniques have made ABSSSI treatment more effective and efficient. This has contributed to market growth and improved patient outcomes.

The ABSSSI treatment market is expected to continue growing in the coming years as the prevalence of ABSSSI continues to rise, awareness of skin health concerns continues to rise, and new treatment options and techniques are developed. However, significant barriers to accessing ABSSSI treatment still exist, especially in low- and middle-income countries where access to health services is often limited. Efforts are underway around the world to address these barriers and improve access to ABSSSI treatment.

ABSSSI: Epidemiology

According to the World Health Organization, skin diseases, including ABSSSI, are among the most common human health disorders, affecting millions of people worldwide. ABSSSI is associated with certain risk factors, such as a weakened immune system, chronic skin conditions, exposure to bacteria, and can affect individuals of all ages and genders, making them more likely to develop infections. increase.

Efforts to improve access to ABSSSI treatment should take into account the specific needs of different age and gender groups, as well as the underlying factors that contribute to the development of ABSSSI, such as hygiene practices, environmental conditions and health status. there is. Addressing these factors can reduce the burden of ABSSSI and ensure effective treatment is available to all individuals regardless of age and gender.

ABSSSI Therapeutic Market Segmentation

The market can be segmented on the basis of type of infectious disease, route of administration, therapeutic channel and region.

Market Breakdown by Type of Infectious Disease

  • Hospital obtains ABSSI

  • Community Obtained ABSSI

  • others

Market breakdown by route of administration

  • Oral

  • Parenteral

  • topical

  • others

Market Breakdown by Treatment Channel

Market breakdown by region

North America

  • united states of america

  • Canada

Europe

  • England

  • Germany

  • France

  • Italy

  • others

Asia Pacific

  • China

  • Japan

  • India

  • ASEAN

  • Australia

  • others

latin america

  • Brazil

  • Argentina

  • Mexico

  • others

middle east and Africa

  • Saudi Arabia

  • United Arab Emirates

  • Nigeria

  • South Africa

  • others

ABSSSI Treatment Market Scenario

The global ABSSSI treatment market has witnessed significant growth over the past few years due to factors such as increasing prevalence of ABSSSI, growing awareness of skin health, and growing demand for innovative treatment options. One of the main drivers of ABSSSI treatment market growth is the increasing prevalence of skin infections.

North America It is currently the largest market for ABSSSI treatment and holds a large share of the global market. The region’s large market share is driven by factors such as high prevalence of ABSSSI, well-established medical infrastructure, and strong investment in research and development.

In addition, increasing adoption of digital health technology and telemedicine further fuels market growth in the following areas: North America. Europe It is also an important market for ABSSSI treatment, England, Germanyand France lead the way. Market growth in this region is driven by factors such as large population base, increasing awareness of skin health issues, and government initiatives to address skin health issues. Additionally, the region has an established healthcare system that supports the delivery of ABSSSI treatment.

Asia Pacific Another region experiencing significant growth in the ABSSSI treatment market. The growth of the market in this region is driven by factors such as the large population base, growing awareness of skin health concerns, and increasing adoption of digital health technologies. Additionally, government efforts to address skin health issues are driving the market growth in the region.

Key players in the global ABSSSI treatment market

The report offers an in-depth analysis of key players involved in the ABSSSI Therapeutics market including business overviews, product portfolios, recent developments and financial analysis. Major companies operating in the market include:

  • Paratech Pharmaceuticals, Inc.

  • Merck

  • Melinta Therapeutics

  • AbbVie Inc.

  • Sand International GmbH

  • Glenmark Pharmaceuticals

  • Teva Pharmaceutical Industries, Inc.

  • Sun Pharmaceutical Industries Co., Ltd.

  • Aceragen Co., Ltd. (Arebas Co., Ltd.)

  • accord health care

  • intus pharmaceutical

  • Fresenius SE & Co. KGaA

  • Zydus Life Science Limited

Main topics covered:

1.First of all

2 Research method

3 Overview

4 Patient profile

5 Current Scenario Assessment and Regulatory Framework

6 Challenges and unmet needs

7 Global Acute Bacterial Skin and Skin Structure Infection Treatment Market

8 North America Acute Bacterial Skin and Skin Structure Infection Treatment Market

9 Europe Acute Bacterial Skin and Skin Structure Infection Treatment Market

10 Asia-Pacific Acute Bacterial Skin and Skin Structure Infection Treatment Market

11 Latin America Acute Bacterial Skin and Skin Structure Infection Treatment Market

12 middle east and Africa Acute Bacterial Skin and Skin Structural Infections Treatment Market

13 Global Acute Bacterial Skin and Skin Structure Infection Treatment Market Dynamics

14 SUPPLIER SITUATION

15 Global Acute Bacterial Skin and Skin Structure Infection Treatment Market – Pharmaceutical Distribution Models (Additional Insights)

16 Payment Methods (Additional Insights)

companies mentioned

  • Paratech Pharmaceuticals, Inc.

  • Merck

  • Melinta Therapeutics

  • AbbVie Inc.

  • Sand International GmbH

  • Glenmark Pharmaceuticals

  • Teva Pharmaceutical Industries, Inc.

  • Sun Pharmaceutical Industries Co., Ltd.

  • Aceragen Co., Ltd. (Arebas Co., Ltd.)

  • accord health care

  • intus pharmaceutical

  • Fresenius SE & Co. KGaA

  • Zydus Life Science Limited

For more information on this report, please visit https://www.researchandmarkets.com/r/r7h88d.

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source of international market research reports and market data. It provides up-to-date data on international and regional markets, key industries, top companies, new products and latest trends.

Media contact:
research and market
Laura WoodSenior Manager
press@researchandmarkets.com

For Eastern Standard Time office hours, please call +1-917-300-0470.
US/Canada Toll Free +1-800-526-8630
For GMT office hours, please call +353-1-416-8900.

US Fax: 646-607-1907
Fax (outside US): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

Sision

Sision

View Original Content: https://www.prnewswire.com/news-releases/global-acute-bacteria-skin-and-skin-structural-infections-treatment-market-report-2023-2031-sector-to- reach-21-7-billion-by-2031-at-a-9-6-cagr-301823159.html

Source Research and Market



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *